Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571972 · ClinicalTrials.gov registry record · Phase 2
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
A Phase 2 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02571972 is a Phase 2 study that has completed, run by Wills Eye. The registered enrollment target is 14 participants.
The verdict
NCT02571972, a Phase 2 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.
Interventions
- DRUG Dorzolamide-timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-02-01 |
| Est. Completion | 2015-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02571972
The ClinicalTrials.gov registry entry for NCT02571972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dorzolamide-timolol is the first listed.
NCT02571972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02571972 about?
NCT02571972 is a clinical study titled "Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.". This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.
What is the current status of trial NCT02571972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-02-01. Estimated completion is 2015-12-20.
What interventions are being tested in trial NCT02571972?
The interventions under investigation include: Dorzolamide-timolol (DRUG).
Who is sponsoring clinical trial NCT02571972?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.